|
SURVEY QUESTIONS
Demographics
1.
Physician
specialty
2.
Country
3.
Geographic
region of practice in the U.S.
4.
Age
General Practices/Projections
5.
Who is
performing interventional procedures at your hospital?
6.
How many
interventional procedures do you perform per month?
7.
Do you
perform peripheral interventions?
8.
Of all the
interventional procedures you perform (both peripheral and
coronary),
what percent of yours are peripheral?
9.
For your
peripheral interventions, which stent platform do you prefer?
10.
Of all
your peripheral procedures (both venous and arterial), what
percent are for venous indications?
11.
Which ONE
of the following peripheral arteries will see the MOST growth in
stent usage/application over the next 2 to 3 years?
12.
Where do
you think your practice will grow the MOST in the next 2-3 years?
13.
Will your
use of stents increase when drug-eluting stents become available?
14.
When drug-coated
stents become available for coronary applications, what percent
of your coronary cases do you anticipate will be performed with
drug-coated stents?
15.
The FDA
should approve stents, balloon and wires by: Vessel?, General
location?
or Vascular or non-vascular clinical indications?
16.
Do you
see a trend in your practice toward use of smaller wires?
17.
Do you
use the Cutting Balloon?
Carotid
Stenting/Stroke
18.
What do
you think the treatment of choice is for a routine carotid
stenosis?
19.
Who is
performing CAS at your institution?
20.
How many
patients do you see per month who are candidates for carotid
stenting?
21.
Do you
perform carotid stenting procedures?
22.
How many
carotid stenting procedures do you perform per month?
23.
Projected
growth in the number of carotid stenting procedures to be
performed
in 2004.
24.
What
product do you currently use the MOST when stenting the carotids?
25.
FDA
approval of stents for carotid indications will affect my
off-label use of stents. (Strongly agree/Strongly disagree)
26.
Have you
received training in carotid stenting?
27.
Do you
plan to perform carotid stenting procedures?
28.
Should
carotid stenting be reserved for the more experienced centers
only?
29.
Should
pre-dilitation be a requirement for carotid stenting?
30.
How
important is the characteristics of the plaque as an indication to
carotid stenting?
31.
Do you
think the Cutting Balloon is applicable in carotids?
32.
Should
recurrent carotid in-stent restenosis be treated with additional
stenting?
33.
Should
indications for brachytherapy be extended to include carotid
stenosis?
34.
Should
carotid stenting be considered in asymptomatic patients with
<70% stenosis?
35.
Based on
your personal experience, word of mouth and research to date, how
promising is carotid stenting?
36.
In your
opinion, what is the MOST important issue remaining to be resolved
before carotid stenting/embolic protection will be widely
endorsed?
37.
Is
intravascular ultrasound available in your institution?
38.
Do you
routinely use intravascular ultrasound?
39.
How is
stroke managed at your institution?
(Conservatively/Aggressively)
40.
How does
your institution prepare for acute stroke?
41.
Do you
think that thrombolysis will be useful?
42.
Which
thrombolytic drug has the best safety, utility, and efficacy
profile?
43.
Over the
next two years, do you anticipate the use of thrombolytic therapy
for
PVD will…
44.
Which area
do you see as the area where thrombolysis will be most useful?
45.
Do you
perform intracranial interventions?
46.
If you do
not currently perform intracranial interventions do you plan to in
the future?
47.
Is MRA
currently available in your practice?
48.
Is FAST
CT currently available in your practice?
Embolic
Protection
49.
Do you
think cerebral protection should be used in all CAS cases?
50.
Carotid
artery stenting should require embolic protection.
(Strongly agree/Strongly
disagree scale)
51.
Iliac
artery interventions should require embolic protection.
(Strongly agree/Strongly disagree scale)
52.
Renal
interventions should require embolic protection.
(Strongly agree/Strongly
disagree scale)
53.
Subclavian
artery interventions should require embolic protection.
(Strongly agree/Strongly
disagree scale)
54.
Which
embolic protection device do you prefer?
55.
In your
opinion, which type of embolic protection device do you feel is
MOST promising?
56.
Is use of
an embolic protection device important during basilar artery
stenting?
57.
In your
opinion, what is the likelihood that embolic protection will one
day be ROUTINELY used in conjunction with vertebral stenting?
Vascular
Sealing Devices
58.
Are you
currently using femoral arteriotomy closure devices for
interventional cases?
59.
If yes, in
what percentage of cases do you use vascular sealing devices post
peripheral intervention?
60.
In what
percentage of cases do you use vascular sealing devices
post-routine cardiac catheterization?
61.
Which of
the following factors is MOST important to you when choosing an
arteriotomy closure device?
Abdominal
Aortic Aneurysm
62.
Do you
perform AAA repairs using stent-grafts?
63.
Do you
have experience with more than one stent-graft design for AAA
repair?
64.
Projected
growth in the number of endovascular
AAA procedures to be
performed
in 2004.
65.
If you
don't perform or plan to perform AAA repairs, why not?
(Choose the MAIN reason)
66.
Have you
received training for AAA repair using stent-grafts?
67.
Which of
the following do you most commonly use to diagnose endoleaks?
Angiography? CT w/contrast? Sonography?
68.
When
should endoluminal grafting be performed?
Superficial
Femoral Artery Stenting
69.
What is
the appropriate therapy for SFA stenosis and occlusion?
70.
If you
perform SFA interventions, what percent do you treat with PTA
alone?
71.
Do you
stent the superficial femoral artery (SFA)?
72.
How many
superficial femoral artery stenting procedures did you perform in
2001?
73.
For SFA
lesions, what type of stent would you use?
74.
What is
your stent of choice for SFA lesions?
75.
Do you
think drug-coated stents will become the stent of choice for SFAs?
76.
Projected
growth in the number of femoral
artery stenting procedures to be performed
in 2004.
77.
What is
the treatment for a long segment SFA occlusion?
78.
For a
suboptimal SFA angioplasty result, what is your next maneuver?
79.
What is
the treatment of choice for symptom limiting claudication?
80.
Patients
with posterior circulation ischemia require angiographic
diagnosis.
(Agree/Disagree scale)
81.
Does
brachytherapy have a role in SFA stenting?
Iliac
Artery Stenting
82.
How many
iliac artery stenting procedures did you perform in 2001?
83.
What
product do you use the MOST when stenting short segments of the
iliac arteries?
84.
What
product do you use the MOST when stenting LONG segments of the
iliac arteries?
85.
Projected
growth in the number of iliac artery stenting procedures to be performed
in 2002.
86.
Have you
received training in iliac artery stenting?
87.
Do you
think stenting is better than balloon angioplasty for common iliac
lesions?
88.
What is
your intervention of choice for common iliac lesions?
89.
For
aorto-ostial common iliac lesions, what type of stent would you
use?
90.
For non-ostial
common iliac and external iliac lesions, what type of stent would
you use?
91.
Is
provisional stenting warranted in the iliac arteries?
92.
Would you
use multiple stents for iliac artery stenting?
93.
What is
the ideal treatment for iliac in-stent restenosis?
Renal
Artery Stenting
94.
How many
patients do you see a month with renal artery stenosis who are
candidates for intervention?
95.
Should
primary angioplasty be the treatment of choice for renal stenosis?
96.
How many
renal artery stenting procedures did you perform in 2001?
97.
What
product do you use the most when stenting the renal arteries?
98.
What is
your overall satisfaction with the stents currently available to
treat renal arterial disease?
99.
FDA
approval of stents for renal artery indications will affect my
off-label use of stents. (Strongly agree/Strongly disagree scale)
100.
Do you
prefer RX (rapid exchange) or OTW (over the wire) systems for
renal interventions?
101.
Projected
growth in the number of renal artery stenting procedures to be performed
in 2002.
102.
Compared
to medical therapy, will renal stenting improve clinical outcomes?
103.
Should
renal artery stenting be reserved for medical failure?
Subclavian/Vertebral
Artery Stenting
104.
Have you received training in
subclavian artery stenting?
105.
How many subclavian artery stenting
procedures did you perform in 2001?
106.
For
subclavian lesions, what type of stent would you use?
107.
What
product do you use the MOST when stenting the subclavian artery?
108.
Projected
growth in the number of subclavian artery stenting procedures to be
performed in 2004.
109.
How many vertebral artery stenting
procedures did you perform in 2002?
110.
Projected
growth in the number of vertebral artery stenting procedures to be performed
in 2004.
© April 2002, Medtech Insight, LLC
|
